5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men

Flávio Adsuara Cadegiani, John McCoy, Carlos Gustavo Wambier, Andy Goren
doi: https://doi.org/10.1101/2020.11.16.20232512

Article Information

doi 
https://doi.org/10.1101/2020.11.16.20232512
History 
  • November 18, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Author Information

  1. Flávio Adsuara Cadegiani, MD, PhD1,
  2. John McCoy, PhD2,*,
  3. Carlos Gustavo Wambier, MD, PhD3 and
  4. Andy Goren, MD2
  1. 1Department of Clinical Endocrinology, Federal University of São Paulo Medical School, Sao Paulo, Brazil
  2. 2Applied Biology, Inc. Irvine, CA, USA
  3. 3Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, USA
  1. ↵*Corresponding author:
    John McCoy, PhD, Applied Biology, Inc., 17780 Fitch, Suite 192, Irvine, CA 92614, johnm{at}appliedbiology.com
Back to top
Posted November 18, 2020.
Download PDF
Data/Code
Email
5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
Flávio Adsuara Cadegiani, John McCoy, Carlos Gustavo Wambier, Andy Goren
medRxiv 2020.11.16.20232512; doi: https://doi.org/10.1101/2020.11.16.20232512
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area